Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Weill Medical College of Cornell University Celgene Corporation |
---|---|
Information provided by: | Weill Medical College of Cornell University |
ClinicalTrials.gov Identifier: | NCT00151203 |
PRIMARY STUDY OBJECTIVES
SECONDARY STUDY OBJECTIVES
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: Clarithromycin, Lenalidomide, Dexamethasone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment |
Official Title: | A Phase II Study of Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) for Newly Diagnosed Subjects With Multiple Myeloma |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |
Weill Medical College of Cornell University | |
New York, New York, United States, 10021 |
Principal Investigator: | Ruben Niesvizky, MD | Weill Medical College of Cornell University |
Study ID Numbers: | 0904-501 |
Study First Received: | September 6, 2005 |
Last Updated: | July 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00151203 |
Health Authority: | United States: Food and Drug Administration |
newly diagnosed multiple myeloma |
Dexamethasone Immunoproliferative Disorders Blood Protein Disorders Hematologic Diseases Blood Coagulation Disorders Lenalidomide Vascular Diseases Paraproteinemias |
Hemostatic Disorders Multiple Myeloma Clarithromycin Hemorrhagic Disorders Multiple myeloma Lymphoproliferative Disorders Dexamethasone acetate Neoplasms, Plasma Cell |
Anti-Inflammatory Agents Anti-Infective Agents Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Hormonal Immune System Diseases Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Gastrointestinal Agents Antiemetics Enzyme Inhibitors |
Hormones Glucocorticoids Pharmacologic Actions Anti-Bacterial Agents Protein Synthesis Inhibitors Neoplasms Autonomic Agents Therapeutic Uses Cardiovascular Diseases Peripheral Nervous System Agents Central Nervous System Agents |